| INTRODUCTION
The diagnosis of Crohn's disease (CD) presents numerous challenges in clinical practice. The symptoms may be mild and nonspecific for many years. 1 There is no gold standard diagnostic test. The nonspecific symptom profile together with the limited accuracy of diagnostic tests may lead to delayed diagnosis, especially in countries where infectious diseases predominate. 2, 3 Both patient-related (delayed reporting to the physician) and physician-related (delay in confirmation of diagnosis) risk factors have been implicated. [2] [3] [4] [5] Recent epidemiological studies have suggested an increasing incidence of IBD in Asia over the last decade 6, 7 Traditionally, these are tuberculosis endemic regions with a high prevalence of intestinal tuberculosis (ITB). There is often a diagnostic dilemma between ITB and CD. 8, 9 since the radiological, endoscopic and histological findings can be inconclusive. Consequentially, an empirical anti-tubercular therapy is commonly given before the diagnosis of CD is confirmed which further delays the initiation of specific treatment. 10 The natural history of CD suggests that increased duration of disease is associated a significantly reduced response to medical therapy with increased complications. 4, [11] [12] [13] It is yet unclear whether this natural course of disease can be altered with medical treatment.
The consequences of a delayed diagnosis vis a vis an early diagnosis and initiation of treatment has not been evaluated in the Asia Pacific region. It is not known whether delayed treatment impacts long-term outcomes of this chronic disease.
This study aimed to assess the diagnostic delay in a large wellestablished and -defined Indian cohort of patients and the subsequent outcome including the stricturing and fistulising complications and the need for surgery. We also analysed the risk factors and reasons for the delay and more specifically whether the use of antitubercular therapy impacted the long-term complications.
| ME TH ODS
The study was conducted at the Asian Institute of Gastroenterology (www.aig.net) in Hyderabad, India. This is a high volume gastroenterology superspeciality hospital with patients from across the coun- The delay was then categorised into two groups (> median and ≤ median, ie 18 months). Diagnosis and initiation of treatment within 1 year of onset of symptoms was considered as early diagnosis. The primary outcome was the development of complications including (1) stenosis, (2) fistula formation and (3) the need for surgery.
Surgery included ileal resection, ileo-caecal resection, colectomy and stricturoplasty. Endoscopic dilatation was not included.
Additional data whether the patient had received anti-tubercular therapy prior to the diagnosis of CD and the response to these drugs were recorded. Anti-tubercular therapy was initiated if there was a diagnostic dilemma between ITB and CD despite clinical endoscopic, histological and radiological assessment. These patients were reassessed after 6 months of treatment or if symptoms persisted after 2 months of treatment. Anti-tubercular therapy usage for ≥ 6 months was considered as complete treatment. The patient was considered to have responded to treatment if there was a reduction in ≥ 2 symptoms of abdominal pain, diarrhoea or weight gain together with a reduction in the CD activity index (CDAI) scores by >100 points. 16 
| STATISTICAL ANALYSIS
The IBD registry runs on Apex healthcare management system software developed by 21 century management solutions, Mumbai, which allows entry of follow-up data at each visit. The data for the CD patients was reviewed for completeness and consistency before entering into Microsoft-Excel. The analysis focused on time to diagnosis of CD and its association with the development of complications including (1) Stenosis, (2) Fistula and (3) Need for surgery.
This included frequency distributions and descriptive statistics.
For continuous variables Mann-Whitney U test was applied, and for categorical variables chi-square was used. The ORs were derived for 2 by 2 contingency data. The diagnostic delay was divided into two groups based on median diagnostic delay (one group ≤ the median and the other group as > median value). We used median diagnostic delay because of high variation in the diagnostic delay (SD, standard deviation was higher mean). The demographic and clinical factors between the two factors were compared.
We used a logistic regression analysis approach (univariate followed by multi-variable models) to determine the association of several binomial (ie, sex, anti-tubercular therapy use, smoking, NSAIDs) and continuous variables (ie, age) with diagnostic delay (ie, dependent variable; continuous). A stepwise method of entry of variables into the multivariate logistic model was done. Logistic regression analysis (univariable and multi-variable models) was also performed separately for all three binomial outcome variables (ie, bowel stenosis; fistula; need for surgery) to study their association with bi-nomial and continuous variables (ie, age and diagnostic delay). In addition,
we did three independent time to event (survival) analysis (KaplanMeier) for bowel stenosis, fistula and need for surgery taking early diagnosis as less than 12 months and late diagnosis >12 months.
The comparison between the two groups was made by log-rank test.
We also calculated the same based on median diagnostic delay (ie, 18 months).
The statistical package for social sciences (SPSS 21th version) was used for the analysis. A P value of <0.05 was considered as statistically significant. The median disease duration from diagnosis was 108 months (range 258; IQR: 28-30).
| RESULTS

| Clinical characteristics of the study population
Overall, the median delay in diagnosis was 18 months (IQR, 6-36). The average diagnostic interval was 25.78 months. 37% were diagnosed more than 2 years since the onset of symptoms.
The history of medications for CD taken by each group of patients was compared (Table S1 ). There was no significant difference in frequency of drug usage within the groups. (Table 2) . Similarly, diagnostic delay (per month) (OR: 1.008, 95% CI:
| Demographic characteristics and outcome measures according to diagnostic delay
1.004-1.012, P < 0.001) was the only risk factor for need for surgery (Table 3) . For fistulising complications, none of the risk factors had significant association (Table 4) . ATT use was significantly associated with stenotic complications (OR: 2.104, 95% CI: 1.394-3.175, P < 0.001) even after adjusting for other risk factors including diagnostic delay (Table 2) .
We conducted a time to event (survival) analysis for early (≤12 months) (326 patients) vs late (>12 months) (394 patients)
for all the three outcomes (ie, stenosis, fistula and surgery). Late diagnosis (>12 months) was associated with higher stenotic complications (P < 0.001, log-rank test) and rate of surgery (P = 0.001), but fistulous complications (P = 0.197) were not different (Figure 1) .
A similar analysis was also done based on median diagnostic delay (18 months). A higher median diagnostic delay (>18 months) was associated with higher stenotic complications (P < 0.001, logrank test) and rate of surgery (P = 0.001), but fistulous complications (P = 0.077) were not different ( Figure S1 ).
ATT was a risk factor associated with significantly higher rate of stenotic complications (P = 0.001, log-rank test) but not fistulising complications (P = 0.063) and need for surgery (P = 0.687) on time to event analysis ( Figure 2 ).
| Anti-tubercular therapy (ATT) use and outcomes of CD
A total of 193 of 720 patients with CD (26.8%%) had received ATT prior to diagnosis due to difficultly in differentiating between ITB and CD with noncharacteristic endoscopic, radiological and histological features (Table S2) . TB cultures and MTB PCR (mycobacterium TB-polymerase chain reaction) from biopsy specimen were negative. (Table 5) .
| DISCUSSION
A delay in diagnosis is common in CD. 4 In Asia, the delay is compounded by the diagnostic dilemma with ITB 7 Recent studies have indicated that an early initiation of treatment can improve outcomes in CD. 13, 14 There are very few studies that have assessed the extent of the delay and its impact on the long-term complications of CD.
This study is the largest study from the Asia-Pacific region to comprehensively evaluate risk factors associated with diagnostic delay, and the effects on the development of stricturing and fistulising complications or need for surgery. Moreover, this study is the first to evaluate the effects of anti-tubercular therapy on the short and long-term outcomes of CD for nearly a decade (median 108 months).
The risk factor for diagnostic delay varies across regions.
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Female, ileal disease, smoking and NSAID intake were significant risk factors associated with diagnostic delay in a Swiss IBD cohort. 4 In Romanian patients, ileal location, smoking and symptom onset during summer were found to be independent risk factors. 13 On the other hand, Nahon et al reported that none of these characteristics were associated with diagnostic delay in a French cohort. 2 We found that the use of anti-tubercular treatment was the single most contributing risk factor for diagnostic delay. Approximately T A B L E 1 Comparison of demographic factors (age, sex, smoking history, location of disease) and outcomes (need for surgery, development of stenosis or fistula) based on median diagnostic delay (≤ 18 mo or >18 mo) one-third of patients in our study received ATT before CD was diagnosed. This highlights that diagnostic challenges between ITB and CD continues to be a common confounder in Asia. 7, 9, 17 An empirical ATT is often advised contributing to the delay in diagnosis by at least 6-9 months. 7 The duration of diagnostic delay has also shown considerable variation across the globe. The median delay in western studies has ranged from 12-24 months. [2] [3] [4] The median delay in our patients was 18 months. We observed that 37% were diagnosed more than 2 years since the onset of symptoms. A smaller study from China of 343 patients reported a delay of 39 months. 5 The longer diagnostic times in Asia compared to the West could be attributed to delayed reporting poor healthcare access and of course the symptoms overlap with infectious diarrhoea and ITB. 7, 9, 17 The natural history of CD suggests increased incidence of complications with increasing duration. 12, 18, 19 This is attributed to the progressive change in an inflammatory disease to a chronic fibro-stenotic with stricturing and fistulising complications. [18] [19] [20] The cumulative risk of developing either stricturing or penetrating complication has ranged from 60% to as high as 88%. 11 Each year 3%-5% progress to surgery and after 20 years up to 70%-80% patients require at least one intestinal surgery. [21] [22] [23] [24] It is not clear whether the natural history of CD is modifiable with early medical therapy. [24] [25] [26] [27] There are very few studies which have analysed whether an early initiation of treatment could prevent long-term complications of CD. 4 We observed that stricturing complications and the need for surgery were significantly higher in patients with >12 months delay when compared to an early diagnosis (≤12 months). Around 40% of patients with >24 m of delay in diagnosis required surgery.
An earlier study by Schoepfer et al also showed that the length of diagnostic delay positively correlated with the occurrence of bowel stenosis and intestinal surgery. 4 In fact Peyrin-Biroulet et al coined the term "early CD" denote CD of less than 2 years duration since diagnosis. 28 We observed that the outcome of disease was significantly improved when treatment was initiated within 1 year of the onset of symptoms. This corroborates the concept of early CD but at the same time suggests that the duration of CD should be assessed from the date of onset of symptoms rather than the diagnosis. It can perhaps be extrapolated therefore that early CD and early initiation of treatment could be a prognostic marker of this disease.
The incidence of fistulising complications did not show any significant difference between the early diagnosis (≤12 months) and diagnostic delay (>12 months) groups. This was also in concordance with the earlier studies. 4 It appears that peri-anal and fistulising disease is a distinct subset of CD and not preventable by early initiation of treatment, nor is it associated with progressive disease. 29 The diagnostic dilemma between ITB and CD and empirical ATT was the single most important contributor towards diagnostic delay.
T A B L E 2 Univariable analysis followed by multi-variable logistic regression to assess the association of stenotic complications with bi-nomial (NSAIDs, smoking, Gender, ATT use) and continuous variables (age and diagnostic delay) Anti-tubercular therapy.
T patients showed no significant benefit of rifampicin and ethambutol vs placebo. 32, 33 However, a recent study has reported clinical response to anti-tubercular therapy in 38% patients with CD. However, only 5% showed endoscopic mucosal healing. 34 The unique therapeutic dilemmas has led to modifications of standard treatment algorithms with interim assessment of response. 35 In our study, there was an initial clinical improvement with antitubercular therapy in almost 50% of patients. However, the incidence of stenotic complications was significantly higher in this group. It is possible that these drugs improve the faecal microbiome profile with a temporary response. 36 The incidence of stenotic complications increased perhaps due to the delay in initiation of treatment for CD.
Our study evaluates the effects of diagnostic delay on long-term outcomes of CD. It clearly highlights that the most important and modifiable factor for a favourable prognosis in CD is an early diagnosis and treatment which can prevent stricturing complications and the need for surgery. Fistulising complications appear independent of the time to treatment initiation. In addition, it has shown that the diagnostic dilemma with ITB leads to the use of empirical anti-tubercular therapy in about one-third of the patients. The use of anti-F I G U R E 1 Time to event analysis done for estimating impact of delayed diagnosis on outcome variables-stenosis (A), fistula (B) and need for surgery (C) in CD. The time to event curves were compared between 326 patients with early diagnosis (≤12 mo) and 394 patients with late diagnosis (>12 mo). P value derived by Log-rank Test F I G U R E 2 Time to event analysis done for estimating impact of anti-tubercular therapy on outcome variables-stenosis (A), fistula (B) and need for surgery (C) in CD. The time to event curves were compared between 193 patients who received empirical anti-tubercular therapy (ATT group) and 527 patients in whom anti-tubercular therapy was not given (non ATT group) P value derived by Log-rank Test tubercular therapy does show initial improvement of clinical symptoms but does not seem to alter the long-term complication rates. In fact the incidence of stenotic complications was significantly higher in those that received anti-tubercular therapy. This was perhaps related to the delay in diagnosis and consequent delayed initiation of treatment.
The primary limitation of this study is that it is not population based and was conducted at a single GI referral centre. A referral bias is possible as patients with severe disease or complications are often referred. There could be a recall bias since we relied on the patients memory for the date of onset of symptoms This though was unlikely to affect the overall accuracy of results since it involved all subsets of patients. In addition, IBS and IBD symptoms can overlap and we did not evaluate these systematically using the Rome criteria or other accepted criteria. However, earlier studies did not show significant difference when patients fulfilling the Rome criteria were excluded. 37 In conclusion, we have shown that diagnostic delay is associated with significantly higher rates of stricturing complications and the need for surgery in a large cohort of CD patients. Anti-tubercular treatment appears to have an initial clinical response but the longterm stenotic complications were significantly higher. Hence, patients on empirical anti-tubercular therapy require close monitoring and follow-up to demonstrate complete mucosal healing and a diagnosis of CD should be considered otherwise. This study has important implications in clinical practice in this part of the world where CD is an emerging disease with increasing incidence over the last decade. It strengthens the concept of early CD and early initiation of treatment. There is a need to increase awareness of the disease to ensure early reporting to the physician minimising patientrelated delay. Likewise the physician must be vigilant to rule out inflammatory bowel disease at the earliest and restrict the physicianrelated delay. Early treatment could ensure the best outcomes for this chronic disease.
T A B L E 5 Demographic factors (age, sex, duration of disease) and outcome variables (need for surgery, development of stenosis or fistula) were compared between the patients who received anti-tubercular therapy (ATT group) and who did not receive ATT (non ATT groups) 
